floxuridine has been researched along with Leukopenia in 20 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Leukopenia: A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 9.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 9.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 7.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "Two patients were diagnosed as advanced breast cancer with multiple bone metastases." | 5.33 | [Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005) |
| "Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma." | 5.27 | Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983) |
| "Twenty-four eligible patients (23 of whom were evaluated) with advanced and metastatic breast cancer were treated at the Saitama Cancer Center every 4 weeks with pirarubicin (30 mg/m2 i." | 5.09 | [Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer]. ( Higashi, Y; Inoue, K; Kurosumi, M; Suemasu, K; Tabei, T, 1999) |
| " The purpose of this study was to compare its therapeutic effect with a standard fluorouracil (FU) regimen in patients with locally advanced or metastatic colorectal cancer." | 5.07 | Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer. ( Amadori, D; Bajetta, E; Calabresi, F; Colleoni, M; Comella, G; Lorusso, V; Marangolo, M; Rosso, R; Scanni, A; Sobrero, A, 1993) |
| "To evaluate the feasibility and efficacy of weekly paclitaxel and 5'-DFUR combination therapy in advanced or recurrent breast cancer, 13 patients were enrolled in this pilot study." | 3.72 | [Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer]. ( Kou, Y; Okamoto, Y; Okuyama, N; Sawada, T; Tominaga, T, 2003) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| "Two patients were diagnosed as advanced breast cancer with multiple bone metastases." | 1.33 | [Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)]. ( Kihara, M; Kontani, K; Yamauchi, A; Yokomise, H, 2005) |
| " However, a WHO grade 4 hematologic toxicity was observed in 9 patients, and 2 toxic deaths were related to severe granulocytopenia and sepsis." | 1.28 | [Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect]. ( Alberto, P; Mermillod, B; Winkelmann, JJ, 1990) |
| "Doxifluridine has therapeutic activity, albeit limited, in advanced rectosigmoid adenocarcinoma." | 1.27 | Phase II study of doxifluridine in advanced colorectal adenocarcinoma. ( Abele, R; Alberto, P; Cavalli, F; Hartmann, D; Hofmann, V; Holdener, EE; Kaplan, S; Ryssel, HJ; Siegenthaler, P, 1983) |
| " The optimal daily dosage was considered to be 800-1,200 mg/body/day." | 1.27 | [Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study]. ( Abe, O; Kimura, K; Kimura, T; Kurihara, M; Nakao, I; Niitani, H; Ohta, K; Saito, T; Urushizaki, I; Yoshida, Y, 1985) |
| "1% of cases; however, it was easily reduced by decreasing the dosage or discontinuing administration of the drug." | 1.27 | [Phase II study of 5'-DFUR in gastrointestinal and breast cancer]. ( Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T, 1985) |
| " 5'-DFUR was less toxic to immune organs and the functions than those by other fluorinated pyrimidines." | 1.27 | [Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT]. ( Fujimoto, K; Ishitsuka, H; Matsuura, N; Miwa, M; Ninomiya, Y; Ryu, M, 1988) |
| "Stomatitis was severe at high doses of DFUR." | 1.26 | Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative. ( Abele, R; Alberto, P; Bollag, W; Germano, G; Heintz, R; Seematter, RJ, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (55.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, PY | 1 |
| Mai, HQ | 1 |
| Luo, DH | 1 |
| Qiu, F | 1 |
| Li, NW | 1 |
| Xiang, YQ | 1 |
| Chen, QY | 1 |
| Zhang, L | 1 |
| Sun, R | 1 |
| Cao, KJ | 1 |
| Guo, L | 1 |
| Deng, MQ | 1 |
| Mo, HY | 1 |
| Guo, X | 1 |
| Zhang, F | 1 |
| Cao, SM | 1 |
| Chen, MY | 1 |
| Guo, Y | 1 |
| Fan, YY | 1 |
| Hu, W | 1 |
| Hua, YJ | 1 |
| Xie, GF | 1 |
| Hong, MH | 1 |
| Okamoto, Y | 1 |
| Tominaga, T | 2 |
| Okuyama, N | 1 |
| Sawada, T | 1 |
| Kou, Y | 1 |
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| ANSFIELD, FJ | 2 |
| Kihara, M | 1 |
| Kontani, K | 1 |
| Yamauchi, A | 1 |
| Yokomise, H | 1 |
| Kemeny, N | 1 |
| Eid, A | 1 |
| Stockman, J | 1 |
| Gonen, M | 1 |
| Schwartz, L | 1 |
| Tetzlaff, E | 1 |
| Paty, P | 1 |
| Abele, R | 2 |
| Alberto, P | 3 |
| Seematter, RJ | 1 |
| Germano, G | 1 |
| Heintz, R | 1 |
| Bollag, W | 1 |
| Kaplan, S | 1 |
| Siegenthaler, P | 1 |
| Hofmann, V | 1 |
| Ryssel, HJ | 1 |
| Hartmann, D | 1 |
| Holdener, EE | 1 |
| Cavalli, F | 1 |
| Yamada, Y | 1 |
| Tsushima, K | 1 |
| Sakata, Y | 1 |
| Saito, S | 1 |
| Ito, T | 1 |
| Sugimoto, N | 1 |
| Ogasawara, H | 1 |
| Tamura, Y | 1 |
| Moriya, N | 1 |
| Komatsu, Y | 1 |
| Bajetta, E | 1 |
| Colleoni, M | 1 |
| Rosso, R | 1 |
| Sobrero, A | 1 |
| Amadori, D | 1 |
| Comella, G | 1 |
| Marangolo, M | 1 |
| Scanni, A | 1 |
| Lorusso, V | 1 |
| Calabresi, F | 1 |
| Inoue, K | 1 |
| Tabei, T | 1 |
| Suemasu, K | 1 |
| Higashi, Y | 1 |
| Kurosumi, M | 1 |
| Lokich, J | 1 |
| Moore, C | 1 |
| Anderson, N | 1 |
| Bern, M | 1 |
| Winkelmann, JJ | 1 |
| Mermillod, B | 1 |
| Niitani, H | 1 |
| Kimura, K | 1 |
| Saito, T | 1 |
| Nakao, I | 1 |
| Abe, O | 1 |
| Urushizaki, I | 1 |
| Ohta, K | 1 |
| Yoshida, Y | 1 |
| Kimura, T | 1 |
| Kurihara, M | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Ninomiya, Y | 1 |
| Ryu, M | 1 |
| Matsuura, N | 1 |
| Fujimoto, K | 1 |
| Miwa, M | 1 |
| Ishitsuka, H | 1 |
| Khazei, AM | 1 |
| Patel, DD | 1 |
| Morgenthaler, FR | 1 |
| MacDonald, AJ | 1 |
| Sanadizadeh, SM | 1 |
| Watkins, E | 1 |
| Moertel, CG | 1 |
| Reitemeier, RJ | 1 |
| Hahn, RG | 1 |
| Ramirez, G | 1 |
| DeConti, RC | 1 |
| Kaplan, SR | 1 |
| Papac, RJ | 1 |
| Calabresi, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
6 trials available for floxuridine and Leukopenia
| Article | Year |
|---|---|
Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therap | 2009 |
Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dexamethasone; Dose- | 2005 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; | 1993 |
[Therapeutic efficacy of pirarubicin cyclophosphamide and doxifluridine in advanced and metastatic breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 1999 |
A controlled comparison of 5-fluoro-2'-deoxyuridine therapy administered by rapid intravenous injection and by continuous intravenous infusion.
Topics: Clinical Trials as Topic; Diarrhea; Drug Eruptions; Floxuridine; Humans; Hyperglycemia; Infusions, P | 1967 |
14 other studies available for floxuridine and Leukopenia
| Article | Year |
|---|---|
[Evaluation of weekly paclitaxel and doxifluridine (5'-DFUR) combination therapy in patients with advanced or recurrent breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 2003 |
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
[Two cases of advanced breast cancer responding to oral chemoendocrine therapy with 5'-deoxy-5-fluorouridine, medroxyprogesterone acetate and cyclophosphamide (DMpC)].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast | 2005 |
Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; | 1982 |
Phase II study of doxifluridine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms | 1983 |
Infusion of floxuridine plus etoposide plus cisplatin in human malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ci | 1991 |
[Doxifluridine toxicity, a fluorouracil analog with low myelosuppressive effect].
Topics: Administration, Oral; Antineoplastic Agents; Bone Marrow; Central Nervous System; Floxuridine; Heart | 1990 |
[Phase II study of 5'-deoxy-5-fluorouridine (5'-DFUR) in patients with malignant cancer--a multi-institutional cooperative study].
Topics: Anorexia; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Administration | 1985 |
[Phase II study of 5'-DFUR in gastrointestinal and breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Diarr | 1985 |
[Antitumor activity and toxicity to the immune system and intestine, of the fluorinated pyrimidines FUra, 5'-DFUR, tegafur and UFT].
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Marro | 1988 |
Chronic infusion of 5-fluoro-2'-deoxyuridine (5-FUDR) into the hepatic artery of the dog.
Topics: Animals; Diarrhea; Dogs; Female; Floxuridine; Gastrointestinal Hemorrhage; Hepatic Artery; Injection | 1970 |
Phase I and II studies of 2'-deoxy-5-(trifluoromethyl)-uridine (NSC-75520).
Topics: Blood Cell Count; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Deoxyuridine; Female; Floxuridin | 1971 |
Continuous intravenous infusions of 5-fluoro-2'-deoxyuridine in the treatment of solid tumors.
Topics: Breast Neoplasms; Diarrhea; Drug Eruptions; Female; Floxuridine; Gastrointestinal Neoplasms; Hemangi | 1973 |